dc.contributor
Institut Català de la Salut
dc.contributor
[Gottschalk C] Yale Medicine Department of Neurology, New Haven, CT, USA. [Gandhi P, Stokes J] AbbVie, North Chicago, IL, USA. [Pozo-Rosich P] Unitat de Cefalees, Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca de Cefalea i Dolor Neurològic, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Christie S] University of Ottawa, Neurology, Ottawa, ON, Canada. [Tassorelli C] Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy. IRCCS C. Mondino Foundation, Pavia, Italy
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Gottschalk, Christopher
dc.contributor.author
Gandhi, Pranav
dc.contributor.author
Christie, Suzanne
dc.contributor.author
Stokes, Jonathan
dc.contributor.author
Pozo-Rosich, Patricia
dc.contributor.author
TASSORELLI, CRISTINA
dc.date.accessioned
2025-02-04T14:36:57Z
dc.date.available
2025-02-04T14:36:57Z
dc.date.issued
2025-01-21T12:35:31Z
dc.date.issued
2025-01-21T12:35:31Z
dc.identifier
Gottschalk C, Gandhi P, Pozo-Rosich P, Christie S, Tassorelli C, Stokes J, et al. Effect of preventive treatment with atogepant on quality of life, daily functioning, and headache impact across the spectrum of migraine: Findings from three double-blind, randomized, phase 3 trials. Cephalalgia. 2024 Dec;44(12):1–14.
dc.identifier
https://hdl.handle.net/11351/12457
dc.identifier
10.1177/03331024241300305
dc.identifier.uri
http://hdl.handle.net/11351/12457
dc.description.abstract
Headache; Migraine disorders; Quality of life
dc.description.abstract
Mal de cap; Trastorns de migranya; Qualitat de vida
dc.description.abstract
Dolor de cabeza; Trastornos de migraña; Calidad de vida
dc.description.abstract
Background: We aimed to assess the effects of preventive migraine treatment with atogepant vs. placebo on patient-reported quality of life and functioning.
Methods: Analyses of patient-reported outcomes from three 12-week, randomized, placebo-controlled trials evaluating preventive migraine treatment with atogepant 60 mg once-daily: ADVANCE (low-frequency episodic migraine [LFEM], 4-8 monthly migraine days [MMDs] and high-frequency episodic migraine [HFEM], 8-14 MMDs), PROGRESS (chronic migraine, CM) and ELEVATE (episodic migraine in those previously failed by two to four classes of oral preventive treatments).
Results: Least squares mean differences (95% confidence interval (CI)) in change from baseline were greater (p < 0.05) for atogepant vs. placebo for Migraine-Specific Quality of Life questionnaire Role Function-Restrictive domain scores at week 12 (ADVANCE: LFEM 12.0 (95% CI = 6.0-18.0), HFEM 9.9 (95% CI = 3.4-16.4); PROGRESS: 6.2 (95% CI = 2.5-9.8); ELEVATE: 17.7 (95% CI = 13.1-22.3)), for Headache Impact Test-6 total scores at week 12 (ADVANCE: LFEM -4.7 (95% CI = -6.7 to -2.7); HFEM -3.4 (95% CI = -5.5 to -1.2); PROGRESS: -2.8 (95% CI = -4.1 to -1.4); ELEVATE: -6.5 (95% CI = -8.3 to -4.7)) and for Activity Impairment in Migraine-Diary-Performance of Daily Activities scores across 12 weeks (ADVANCE: LFEM -2.3 (95% CI = -3.9 to -0.7), HFEM -4.5 (95% CI = -6.9 to -2.2); PROGRESS: -3.4 (95% CI = -5.3 to -1.5); ELEVATE: -4.7 (95% CI = -6.4 to -3.1)).
Conclusions: Preventive migraine treatment with atogepant 60 mg once-daily vs. placebo improved measures of migraine-related quality of life and functioning among participants with different headache frequencies and histories of previous treatment failure.Trial Registration: ClinicalTrials.gov: NCT03777059 (ADVANCE); NCT03855137 (PROGRESS); NCT04740827 (ELEVATE).
dc.description.abstract
This study was sponsored and funded by Allergan (now AbbVie).
dc.format
application/pdf
dc.publisher
SAGE Publications
dc.relation
Cephalalgia;44(12)
dc.relation
https://doi.org/10.1177/03331024241300305
dc.rights
Attribution-NonCommercial 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Migranya - Tractament
dc.subject
Migranya - Prevenció
dc.subject
Pacients - Satisfacció
dc.subject
Avaluació de resultats (Assistència sanitària)
dc.subject
DISEASES::Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Headache Disorders::Headache Disorders, Primary::Migraine Disorders
dc.subject
Other subheadings::Other subheadings::Other subheadings::/prevention & control
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome
dc.subject
HEALTH CARE::Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Health Status::Quality of Life
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Calcitonin Gene-Related Peptide Receptor Antagonists
dc.subject
Other subheadings::Other subheadings::/therapeutic use
dc.subject
ENFERMEDADES::enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::trastornos con cefaleas::cefaleas primarias::trastornos migrañosos
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/prevención & control
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento
dc.subject
ATENCIÓN DE SALUD::ambiente y salud pública::salud pública::medidas epidemiológicas::demografía::estado de salud::calidad de vida
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::antagonistas del receptor del péptido relacionado con el gen de la calcitonina
dc.subject
Otros calificadores::Otros calificadores::/uso terapéutico
dc.title
Effect of preventive treatment with atogepant on quality of life, daily functioning, and headache impact across the spectrum of migraine: Findings from three double-blind, randomized, phase 3 trials
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
